Submit Deal

ALVOTECH

HQ - Reykjavik

Summary

Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines.

Deals Overview

Total Deals3

Valued Deals2

Total Value£ 1.72 B

Avg. Deal Size£ 859 M

Market Context

Senior Management

Robert Wessman
Chairman and CEO
Mark Levick
CEO
Joel Morales
CFO

Sort

cooley

HQ - Palo Alto

legal advisors (1)

1 Shared Deal

1 For

£ 1.70 B

Total Value

morgan stanley

HQ - New York

financial advisors (2)

2 Shared Deals

1 For | 1 Opposite

£ 3.40 B

Total Value

credit suisse

HQ - Zürich

financial advisors (2)

2 Shared Deals

1 For | 1 Opposite

£ 3.40 B

Total Value

icr

HQ - New York, United States

pr advisors (1)

1 Shared Deal

1 For

£ 1.70 B

Total Value

white & case

HQ - New York

legal advisors (1)

1 Shared Deal

1 For

£ 1.70 B

Total Value

kirkland & ellis

HQ - Chicago, United States

legal advisors (1)

1 Shared Deal

1 Opposite

£ 1.70 B

Total Value

shearman & sterling

HQ - New York

legal advisors to financial advisors (1)

1 Shared Deal

1 Opposite

£ 1.70 B

Total Value

deutsche bank

HQ - Frankfurt

financial advisors (1)

1 Shared Deal

1 Opposite

£ 1.70 B

Total Value

citigroup

HQ - New York

financial advisors (1)

1 Shared Deal

1 Opposite

£ 1.70 B

Total Value

king & spalding

HQ - Atlanta, United States

legal advisors (1)

1 Shared Deal

1 Opposite

£ 1.70 B

Total Value

sard verbinnen & co

pr advisors (1)

1 Shared Deal

1 Opposite

£ 1.70 B

Total Value

carnegie investment bank

HQ - Copenhagen

financial advisors (1)

1 Shared Deal

1 For

£ 21 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy